BTIG lowered the firm’s price target on Globus Medical (GMED) to $88 from $94 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the MedTech space.

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target of $88.00. The company’s shares closed last Friday ...

Get Access To Every Broadway Story Unlock access to every one of the hundreds of articles published daily on BroadwayWorld by logging in with one click. Nicole Scherzinger recently added six more ...